PharmaCyte Biotech, Inc. (PMCB)
Data as of , from SEC Form 4 filings.
See up to 3 months of PMCB. The 7-day demo opens the 1M and 3M ranges and puts PMCB on your watchlist.
Start 7-day demoLatest PMCB insider trades
Joshua Silverman - OfficerOpen-market purchase$23K- Joshua Silverman - OfficerOpen-market purchase$24K
About PharmaCyte Biotech, Inc. (PMCB)
The SEC lists PharmaCyte Biotech, Inc. under CIK 0001157075, in biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
PMCB Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Other acquisition / disposition | 4 | 0 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PMCB insider transactions (Form 4)
2815 Form 4 filings on record, the earliest from Dec 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Wayne Remell Walker - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
 Michael M. Abecassis - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Jonathan Schechter - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Robert Weinstein - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Robert Weinstein - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Wayne Remell Walker - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Jonathan Schechter - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Michael M. Abecassis - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 30,000 | $0.78 | $23K | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 30,000 | $0.79 | $24K | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 40,000 | $0.83 | $33K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.78 | $16K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.79 | $16K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.84 | $17K | |
| Robert Weinstein - Director | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Robert Weinstein - Director | Tax withholding / forfeiture | Common Stock | 33,750 | $1.02 | $34K | |
| Robert Weinstein - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Wayne Remell Walker - Director | Grant or award | Common Stock | 37,500 | $0.00 | - | |
| Wayne Remell Walker - Director | Tax withholding / forfeiture | Common Stock | 16,875 | $1.02 | $17K | |
| Wayne Remell Walker - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Joshua Silverman - Officer | Grant or award | Common Stock | 575,000 | $0.00 | - | |
| Joshua Silverman - Officer | Tax withholding / forfeiture | Common Stock | 258,750 footnote F1 | $1.02 | $264K | |
| ||||||
| Jonathan Schechter - Director | Grant or award | Common Stock | 150,000 | $0.00 | - | |
| Jonathan Schechter - Director | Tax withholding / forfeiture | Common Stock | 67,500 | $1.02 | $69K | |
| Jonathan Schechter - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Michael M. Abecassis - Director | Grant or award | Common Stock | 37,500 | $0.00 | - | |
| Michael M. Abecassis - Director | Tax withholding / forfeiture | Common Stock | 16,875 | $1.02 | $17K | |
| Michael M. Abecassis - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
PMCB insider trading FAQ
What is the latest insider trade for PMCB?
PharmaCyte Biotech, Inc. (PMCB) had 4 insider filings in the last 90 days, with the most recent on 2026-07-17. The full record for PMCB runs to 15 Form 4 filings, the earliest from 2025-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PMCB stock?
No insider purchases of PMCB were filed in the last 90 days. 6 purchases are on record for this company.
How many insiders are selling PMCB stock?
No insider sales of PMCB were filed in the last 90 days.
Where can I see PMCB SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PMCB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Wayne Remell Walker view on EDGAR
- - Michael M. Abecassis view on EDGAR
- - Jonathan Schechter view on EDGAR
- - Robert Weinstein view on EDGAR
- - Robert Weinstein view on EDGAR
- - Wayne Remell Walker view on EDGAR
- - Jonathan Schechter view on EDGAR
- - Michael M. Abecassis view on EDGAR
- - Joshua Silverman view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PMCB's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PMCB with a 7-day demo
- PMCB on your watchlist
- Every PMCB Form 4 filing on record
- Up to 3 months of PMCB price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
